BiotechTube

Anlotinib Hydrochloride

Phase 2UNKNOWN
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Soft Tissue Sarcoma

Conditions

Soft Tissue Sarcoma

Trial Timeline

Apr 11, 2019 → May 30, 2024

NCT ID
NCT03890068

About Anlotinib Hydrochloride

Anlotinib Hydrochloride is a phase 2 stage product being developed by Sun Pharmaceutical for Soft Tissue Sarcoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT03890068. Target conditions include Soft Tissue Sarcoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03890068Phase 2UNKNOWN

Competing Products

20 competing products in Soft Tissue Sarcoma

See all competitors
ProductCompanyStageHype Score
Olaratumab + Doxorubicin + Ifosfamide + MesnaEli LillyPhase 1
33
Eribulin mesylate 1.4 mg/m^2 intravenous + Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IVEisaiPhase 3
77
Eribulin mesylateEisaiPre-clinical
23
E7389EisaiPhase 2
52
eribulin mesylateEisaiPhase 2
52
Olaratumab + Gemcitabine + Docetaxel + PlaceboEli LillyPhase 1/2
41
LY573636-sodiumEli LillyPhase 2
52
OlaratumabEli LillyPre-clinical
23
Olaratumab + Doxorubicin + PlaceboEli LillyPhase 3
77
Olaratumab + DoxorubicinEli LillyPhase 1
33
Olaratumab + DoxorubicinEli LillyPhase 1
33
Olaratumab + Pembrolizumab (KEYTRUDA®)Eli LillyPhase 1
33
Olaratumab + doxorubicinEli LillyPhase 1/2
41
TrabectedinJohnson & JohnsonPre-clinical
23
Doxorubicin + Trabectedin + DexamethasoneJohnson & JohnsonPhase 1
33
Apatinib Mesylate, doxorubicin, ifosfamideJiangsu Hengrui MedicinePhase 2
52
Camrelizumab in Combination With Neoadjuvant ChemotherapyJiangsu Hengrui MedicinePhase 2
52
Durvalumab and Tremelimumab + DoxorubicinAstraZenecaPhase 2
52
Standard arm: Trabectedin in monotherapy + Experimental arm: Trabectedin + OlaparibAstraZenecaPhase 2
52
trabectedin + olaparibAstraZenecaPhase 1
33

Other Products from Sun Pharmaceutical

Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85